ClinicalTrials.Veeva

Menu

Dexmedetomidine Versus Magnesium Infusion in Reducing Agitations in Pediatric Patients Undergoing Adenotonsillectomy

A

Ain Shams University

Status

Unknown

Conditions

Postoperative Agitations in Pediatric Patients

Treatments

Drug: Normal saline
Drug: Magnesium Sulphate
Drug: Dexmedetomidine

Study type

Interventional

Funder types

Other

Identifiers

NCT05164627
Ain Shams University hospital

Details and patient eligibility

About

The aim of this study is evaluating the efficacy and safety of dexmedetomidine versus Magnesium for reducing emergence agitation after adenotonsillectomy in children.

Secondary outcome is to reduce child needs for analgesics and to reduce their dose.

Full description

Preoperatively, Intravenous access using EMLA cream will be established in the ward. Child will be introduced to information about GA, OR and surgery. This information will include pictures of the staff and the OR, facemask, blood pressure cuff, etc. The child will move from ward to Pre-Anesthesia Care Unit accompanying his/her parents and anesthesia doctor to establish bonding. Cooperation on induction will be evaluated by using four-point scale with score of 1 to 2 being satisfactory and 3 to 4 being unsatisfactory. If the child develop agitation (Score 3 or 4) emergency Midazolam 0.1 mg/kg IV will be given and the child will be ruled out of study.

Monitors for non-invasive blood pressure, heart rate, electrocardiogram (ECG), pulse oximetry (SpO2) will be attached. Induction of anesthesia will be done using 8% Sevoflurane in oxygen gas with Atracurium 0.5 mg/kg and fentanyl 0.5 mcg/kg to facilitate tracheal intubation. The patients will be divided into three groups:

oGroup A (Dexmedetomidine Group): patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.

oGroup B (Magnesium Group): patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.

oGroup C (Control Group): Patients will receive Normal Saline 0.9% infusion

Maintenance of anesthesia will be done by using of Sevoflurane 2% in oxygen gas. Controlled mechanical ventilation will be done to maintain normocapnia. Rescue doses of Fentanyl (0.5 mcg/kg) will be given if the patient develop pain. Intraoperative pain is defined as development of Tachycardia (> 20% of baseline heart rate reading) and Hypertension (>20% of Baseline Mean Arterial Blood Pressure reading) .

Enrollment

40 estimated patients

Sex

All

Ages

4 to 12 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • ASA I or II.
  • Age group: 4-12 years old.
  • The procedure expected to be completed within 1 hour.

Exclusion criteria

  • Patients with expected difficult airway management.
  • lack of consent.
  • known adverse effects to dexmedetomidine.
  • Mental retardation developmental delay, or neurological or psychiatric illness that may associate with agitation (cerebral palsy, seizure..etc.)
  • Hemodynamically unstable patients.
  • Persistent cough or high airway secretions.
  • Clinical signs of active infectious disease.
  • Coagulopathy (INR >1.5).
  • Obesity (BMI >30 Kg/m2 ).
  • Surgical complication

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

40 participants in 3 patient groups, including a placebo group

Group A
Active Comparator group
Description:
patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
Treatment:
Drug: Dexmedetomidine
Group B
Active Comparator group
Description:
patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
Treatment:
Drug: Magnesium Sulphate
Group C
Placebo Comparator group
Description:
Patients will receive Normal Saline 0.9% infusion
Treatment:
Drug: Normal saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems